Active immunization for simultaneous vaccination against measles, mumps, and rubella in patients ?12 months of age

Vaccine; Vaccine, Live (Viral)

Onset of action: The median seroconversion after 1 vaccine dose is 96% (measles), 99% (rubella), mumps (94%) (CDC/ACIP [McLean 2013]). Duration: The median duration of immunity after 2 doses is ?15 years for all components of the vaccine (CDC/ACIP [McLean 2013]).

Hypersensitivity to measles, mumps, and/or rubella vaccine or any component of the formulation (including neomycin); current febrile respiratory illness or other febrile infection; patients receiving immunosuppressive therapy (does not include corticosteroids as replacement therapy); primary and acquired immunodeficiency states; individuals with blood dyscrasias, leukemia, lymphomas, or other malignant neoplasms affecting the bone marrow or lymphatic systems; family history of congenital or hereditary immunodeficiency (until immune competence in the vaccine recipient is demonstrated); pregnancy

C

The manufacturer recommends that caution be used if administered to nursing women. Breastfeeding is not a contraindication to vaccination. Breastfeeding infants should be vaccinated according to the recommended schedules (ACIP [Kroger 2017]).

Frequency not defined: Cardiovascular: Syncope, vasculitis Central nervous system: Acute disseminated encephalomyelitis, ataxia, dizziness, Guillain-Barr? syndrome, headache, irritability, malaise, nerve deafness, paresthesia, polyneuropathy, retrobulbar neuritis, seizure, subacute sclerosing panencephalitis, transverse myelitis Dermatologic: Erythema multiforme, IgA vasculitis (Henoch-Schnolein purpura/acute hemorrhagic edema of infancy), morbilliform rash, pruritus, rash, Stevens-Johnson syndrome, urticaria Endocrine & metabolic: Diabetes mellitus Gastrointestinal: Diarrhea, nausea, pancreatitis, parotitis, sore throat, vomiting Genitourinary: Epididymitis, orchitis Hematologic & oncologic: Leukocytosis, lymphadenopathy (regional), purpura, thrombocytopenia Hypersensitivity: Anaphylactoid reaction, anaphylaxis, angioedema Infection: Atypical measles Local: Injection site reaction (including burning, induration, redness, stinging, swelling, tenderness, vesiculation, wheal and flare) Neuromuscular & skeletal: Arthropathy (arthralgia/arthritis: Women 12% to 26%; children ?3%), myalgia, panniculitis Ophthalmic: Conjunctivitis, oculomotor nerve paralysis, optic neuritis, optic papillitis, retinitis Otic: Otitis media Respiratory: Bronchospasm, cough, pneumonia, rhinitis Miscellaneous: Febrile seizures, fever <1%, postmarketing, and/or case reports: Aseptic meningitis (associated with Urabe strain of mumps vaccine), brain disease, encephalitis

SubQ: 0.5 mL per dose; 1 or 2 doses administered at least 28 days apart based upon the following criteria (CDC/ACIP [McLean 2013]) The minimum interval between 2 doses of MMR vaccine is 28 days (CDC/ACIP [McLean 2013]).

Children ?12 months: SubQ: 0.5 mL per dose. One dose is recommended at 12 to 15 months of age and repeated at 4 to 6 years of age; the second dose is recommended prior to entering kindergarten or first grade.

There are no dosage adjustments provided in manufacturer's labeling.

There are no dosage adjustments provided in manufacturer's labeling.

store between 2-8 degree C